- Home
- VABK vs ACIU Comparison
VABK vs ACIU Comparison
Compare VABK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VABK
- ACIU
- Stock Information
- Founded
- VABK 1998
- ACIU 2003
- Country
- VABK United States
- ACIU Switzerland
- Employees
- VABK N/A
- ACIU N/A
- Industry
- VABK Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- VABK Finance
- ACIU Health Care
- Exchange
- VABK Nasdaq
- ACIU Nasdaq
- Market Cap
- VABK 203.8M
- ACIU 213.3M
- IPO Year
- VABK N/A
- ACIU 2016
- Fundamental
- Price
- VABK $38.80
- ACIU $2.90
- Analyst Decision
- VABK
- ACIU Strong Buy
- Analyst Count
- VABK 0
- ACIU 2
- Target Price
- VABK N/A
- ACIU $10.00
- AVG Volume (30 Days)
- VABK 10.1K
- ACIU 343.9K
- Earning Date
- VABK 10-24-2025
- ACIU 11-04-2025
- Dividend Yield
- VABK 3.71%
- ACIU N/A
- EPS Growth
- VABK 14.13
- ACIU N/A
- EPS
- VABK 3.31
- ACIU N/A
- Revenue
- VABK $56,012,000.00
- ACIU $36,362,036.00
- Revenue This Year
- VABK N/A
- ACIU N/A
- Revenue Next Year
- VABK N/A
- ACIU $1,022.98
- P/E Ratio
- VABK $11.72
- ACIU N/A
- Revenue Growth
- VABK 7.97
- ACIU 86.71
- 52 Week Low
- VABK $33.66
- ACIU $1.43
- 52 Week High
- VABK $44.57
- ACIU $3.99
- Technical
- Relative Strength Index (RSI)
- VABK 49.63
- ACIU 47.76
- Support Level
- VABK $37.80
- ACIU $2.89
- Resistance Level
- VABK $41.65
- ACIU $3.21
- Average True Range (ATR)
- VABK 0.88
- ACIU 0.33
- MACD
- VABK 0.09
- ACIU -0.08
- Stochastic Oscillator
- VABK 37.88
- ACIU 3.95
About VABK Virginia National Bankshares Corporation
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.